Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. reports company developments for a commercial-stage medical technology and healthcare business centered on neurohealth therapies. Its recurring updates cover the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation platform cleared by the U.S. Food and Drug Administration for adults with major depressive disorder, adjunctive use in obsessive-compulsive disorder, anxious depression symptoms in adults with MDD, and first-line adjunctive treatment of MDD in adolescent patients aged 15-21.
News about STIM also covers operating results, U.S. and international system revenue, clinic services added through the completed Greenbrook acquisition, SPRAVATO-related clinic activity, executive and board changes, inducement equity awards, shareholder engagement, and cost-structure actions.
Neuronetics (NASDAQ: STIM) reported its Q4 and full-year 2024 financial results, highlighting significant strategic developments. The company completed the acquisition of Greenbrook TMS on December 9, 2024, and secured $10 million in additional funding from Perceptive Advisors.
Q4 2024 revenue reached $22.5 million, up 11% year-over-year, with U.S. NeuroStar system revenue at $3.8 million and treatment session revenue at $12.9 million. Full-year 2024 revenue was $74.9 million, a 5% increase from 2023.
The company reported a Q4 net loss of $(12.2) million and a full-year net loss of $(43.2) million. In February 2025, Neuronetics completed a secondary offering raising $18.9 million. The company has executed actions to realize over $21 million of the targeted $22 million in annual cost synergies related to the Greenbrook acquisition.
Looking ahead, Neuronetics projects Q1 2025 revenue between $28-30 million and full-year 2025 revenue of $145-155 million. The company expects to achieve cash flow positivity by Q3 2025.
Neuronetics (NASDAQ: STIM) has announced the granting of inducement awards consisting of Restricted Stock Units (RSUs) representing 24,750 shares of common stock to three new non-executive employees. The awards were approved by the company's Compensation Committee in compliance with NASDAQ Listing Rule 5635(c)(4).
The RSU grants have different vesting schedules: three grants will vest in equal installments over three years on the first, second, and third anniversaries of the grant date, while one grant will vest over four years on the second, third, and fourth anniversaries. All grants are contingent upon continued employment with the company through the vesting dates and are subject to the Neuronetics 2020 Inducement Plan terms.
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders treatment solutions, has announced it will release its fourth quarter 2024 financial and operating results before the market opens on Tuesday, March 4, 2025.
The company will host a conference call to discuss the results at 8:30 a.m. Eastern Time on the same day. Investors can access the live webcast in listen-only mode, and telephone participants are encouraged to register and join 10 minutes before the event start.
Neuronetics (NASDAQ: STIM) has announced the granting of inducement awards consisting of Restricted Stock Units (RSUs) representing 15,750 shares of common stock to two new non-executive employees. The awards, approved by the company's Compensation Committee under NASDAQ Listing Rule 5635(c)(4), serve as material inducements for employment. These RSUs will vest in equal installments over three years on the first, second, and third anniversaries of the grant date, contingent on continued employment. The awards are governed by the Neuronetics 2020 Inducement Plan.
Neuronetics (NASDAQ: STIM) has priced its previously announced underwritten public offering of 8,000,000 shares of common stock at $2.25 per share, expecting to raise approximately $18 million in gross proceeds before deducting expenses. The company has granted underwriters a 30-day option to purchase up to an additional 1,200,000 shares.
The offering is expected to close around February 10, 2025. Canaccord Genuity is acting as sole bookrunner. The net proceeds will be used for general corporate purposes, including sales and marketing, R&D activities, potential acquisitions, inventory purchases, administrative matters, working capital, and capital expenditures.
Neuronetics (NASDAQ: STIM) has announced the launch of an underwritten public offering of its common stock. The company plans to grant the underwriter, Canaccord Genuity , a 30-day option to purchase up to an additional 15% of the shares offered in the public offering. All shares will be offered by the company.
The offering will be conducted under a shelf registration statement previously filed with the SEC on November 9, 2022, and declared effective on November 14, 2022. The final terms, size, and completion of the offering are subject to market conditions and there is no guarantee of completion.
Neuronetics (NASDAQ: STIM) has announced two peer-reviewed publications in the inaugural edition of the Transcranial Magnetic Stimulation journal, highlighting significant findings about TMS therapy for depression. The first publication demonstrates that transcranial magnetic stimulation (TMS) produces universal improvement in depressive symptoms. The second study reveals that the Patient Health Questionnaire-9 (PHQ-9) shows greater sensitivity compared to the Quick Inventory of Depressive Symptomatology: Self-Report (QIDS-SR) in measuring TMS outcomes.
These publications aim to advance mental health treatment through research and provide clinicians with better tools for patient care. According to Keith J. Sullivan, President and CEO, these findings reinforce TMS's effectiveness in treating depression symptoms while offering insights for more precise clinical care.
Neuronetics (NASDAQ: STIM) announced its preliminary unaudited 2024 financial results and issued 2025 guidance. For 2024, the company reported fourth-quarter revenue of $22.1 million and full-year revenue of $74.5 million. The acquisition of Greenbrook TMS was completed on December 9, 2024, contributing to these figures. The pro forma revenue for Q4 2024 was $34.7 million, while for the full year, it was $129.8 million.
Neuronetics expects 2025 revenue to grow by 12%-19%, reaching between $145 million and $155 million. The company also anticipates achieving over $22 million in annualized cost synergies and aims to be cash flow positive by Q3 2025. Key highlights include the successful integration of Greenbrook TMS, the launch of the Better Me Provider program, and FDA clearance for NeuroStar Advanced Therapy as a first-line add-on treatment for adolescents with depression.
The Better Me Provider program, launched in July 2024, has shown significant improvements in patient care and accessibility. Additionally, the FDA clearance in March 2024 expanded the addressable market for Neuronetics' NeuroStar TMS Therapy by 35%, targeting adolescents aged 15-21 with major depressive disorder.
Neuronetics (NASDAQ: STIM) has announced the granting of inducement awards to a new employee, Bill Leonard, as approved by the Company's Board of Directors' Compensation Committee. The award consists of 50,000 Performance Restricted Stock Units (PRSUs) that will vest in equal installments on December 31, 2025, 2026, and 2027. The vesting is contingent upon certain employees maintaining their employment with either Neuronetics or Greenbrook TMS Inc. through December 31, 2025. These awards were granted under the Company's 2020 Inducement Incentive Plan and comply with NASDAQ Listing Rule 5635(c)(4).
Neuronetics (NASDAQ: STIM) has announced the granting of inducement awards to new employees, approved by the Company's Board Compensation Committee under NASDAQ Listing Rule 5635(c)(4). The awards include Performance Restricted Stock Units (PRSUs) and Restricted Stock Units (RSUs) subject to the 2020 Inducement Incentive Plan.
The PRSUs will vest based on achieving cash flow breakeven targets: 25% for Q2 2025, 50% for Q3 2025, and 25% for Q4 2025. Key recipients include Bill Leonard (100,000 PRSUs), Andy Crish, Geoff Grammer, and Peter Willett (60,000 PRSUs each). RSUs were granted to multiple employees with various vesting schedules over 3-4 years.